Pediatric-Specific Conditions That Risk Adjust — Clinical Documentation Guide (2026)

🔍 Definition

Pediatric risk adjustment refers to the statistical process of modifying capitation payments or predicted healthcare expenditures to account for the health status and expected costs of children enrolled in managed care plans. Unlike adult Medicare risk adjustment (which uses CMS-HCC v28), pediatric populations are primarily risk-adjusted under two major frameworks:

• CDPS+Rx (Chronic Illness and Disability Payment System with Rx) — the dominant model used by state Medicaid programs for children, developed at UC San Diego. It groups diagnoses into clinical categories and assigns relative weights to predict costs for Medicaid managed care enrollees, including children with special health care needs (CSHCN).
• HHS-HCC (Hierarchical Condition Categories for the ACA exchanges) — used under the Affordable Care Act (ACA) risk adjustment program for individual and small group commercial and exchange plans. This model includes a separate child age factor applied to condition weights, making it the primary risk adjustment model for children enrolled in ACA Marketplace plans.

Pediatric-specific conditions that risk adjust are ICD-10-CM-coded diagnoses that, when documented and coded accurately, trigger a HHS-HCC category or CDPS/Medicaid category assignment, thereby increasing the risk score and expected payment for that child’s health plan. Accurate documentation directly affects plan revenue, quality measurement, and downstream resource allocation for complex pediatric patients.

CMS-HCC v28 (the Medicare model) has extremely limited pediatric application because Medicare covers children only in rare circumstances (e.g., ESRD or certain disability categories). For the vast majority of pediatric coding and risk adjustment, coders and CDI specialists should focus on HHS-HCC (commercial/exchange) and state-specific CDPS+Rx (Medicaid).

🗂️ Alternative Terminology

Clinicians, health plan staff, and coding professionals use varying terminology when discussing pediatric risk-adjusting conditions. The table below maps common alternative terms.

🩺 Signs & Symptoms

Because this guide covers a spectrum of pediatric conditions rather than a single diagnosis, signs and symptoms vary by category. The following summarizes clinical presentations that should prompt coders and CDI specialists to query for risk-adjusting diagnoses:

• Hematologic: Recurrent vaso-occlusive pain crises, acute chest syndrome, stroke/TIA in young patients (sickle cell D57.xx); prolonged bleeding, hemarthrosis, spontaneous bruising (hemophilia D66–D68).
• Pulmonary/metabolic: Chronic productive cough, failure to thrive, recurrent pulmonary infections, pancreatic insufficiency (cystic fibrosis E84.xx); persistent wheezing, nocturnal symptoms, frequent ER visits (severe persistent asthma J45.50–J45.51).
• Congenital/genetic: Characteristic dysmorphic features, hypotonia, developmental milestones delay, cardiac defects (Down syndrome Q90; Trisomy 13/18 Q91.x); murmur, cyanosis, poor feeding in newborns (major congenital heart disease).
• Neurological/neuromuscular: Hypotonia, absent deep tendon reflexes, progressive weakness (spinal muscular atrophy G12.0–G12.29); proximal muscle weakness, Gowers’ sign (muscular dystrophy G71.0); recurrent seizures (epilepsy G40.x); spastic diplegia or hemiplegia (cerebral palsy G80.x).
• Behavioral/developmental: Social communication deficits, restricted/repetitive behaviors (autism spectrum F84.0–F84.9); intellectual functioning <70 with adaptive deficits (intellectual disabilities F70–F79); inattention, hyperactivity, impulsivity with significant functional impairment and comorbidities (ADHD F90.x); speech/language regression, global developmental delay (developmental delay F88, F89).
• Endocrine/metabolic: Polyuria, polydipsia, DKA, insulin dependence from onset (type 1 diabetes E10.x); weight z-score ≥95th percentile, acanthosis nigricans (pediatric severe obesity Z68.53–Z68.54).
• Growth/nutritional: Weight-for-age <5th percentile, faltering weight trajectory, inadequate caloric intake (failure to thrive R62.51; malnutrition E44.x); prematurity-related feeding difficulties (preterm newborn P07.xx).
• Oncologic: Lymphadenopathy, unexplained fever, pallor, bruising, bone pain (leukemia/lymphoma C00–C96).

🧭 Differential Diagnosis

CDI and coding professionals should consider the following differential groupings when reviewing pediatric records for risk-adjusting conditions. Not all presenting symptoms map to the highest-weighted HCC — specificity matters.

📋 Clinical Indicators for Coders/CDI

The following clinical indicators should be verified in the medical record before assigning risk-adjusting pediatric diagnoses. Documentation must support the specificity required for the ICD-10-CM code selected.

🦴 Anatomy & Pathophysiology

This section summarizes the pathophysiology of the major pediatric risk-adjusting condition groups to help coders understand the clinical basis for documentation specificity requirements.

Hematologic Disorders

Sickle cell disease (D57.xx): An autosomal recessive hemoglobinopathy caused by a point mutation in the beta-globin gene, resulting in hemoglobin S polymerization under hypoxic conditions. This causes red blood cell sickling, vaso-occlusion, hemolytic anemia, and progressive organ damage. The most common form (HbSS) is associated with the highest morbidity. Acute chest syndrome, stroke, splenic sequestration, and pulmonary hypertension are life-threatening complications. (NHLBI Sickle Cell Disease)

Hemophilia (D66–D68): X-linked recessive deficiency of coagulation factor VIII (Hemophilia A, D66) or factor IX (Hemophilia B, D67), resulting in impaired secondary hemostasis. Characterized by spontaneous or trauma-induced hemarthroses, intramuscular bleeds, and CNS hemorrhage in severe cases. Inhibitor development (alloantibodies to replacement factor) significantly increases treatment complexity. (CDC Hemophilia)

Pulmonary/Metabolic

Cystic fibrosis (E84.xx): Autosomal recessive disorder caused by mutations in the CFTR gene encoding the cystic fibrosis transmembrane conductance regulator chloride channel. Defective chloride transport leads to viscous mucus in airways (chronic infection, bronchiectasis, respiratory failure), exocrine pancreatic insufficiency, and infertility. The F508del mutation accounts for ~70% of CF alleles. CFTR modulators (ivacaftor, elexacaftor/tezacaftor/ivacaftor) have transformed outcomes. (Cystic Fibrosis Foundation)

Severe persistent asthma (J45.50): Chronic inflammatory airway disease characterized by hyperresponsiveness and reversible airflow obstruction. Severity classification by NHLBI EPR-3 guidelines considers daytime symptoms, nighttime awakenings, SABA use, activity limitation, FEV1/FVC, and exacerbation frequency. Severe persistent requires high-dose ICS ± adjunctive therapy; biologics (dupilumab, omalizumab, mepolizumab) now indicated for pediatric severe asthma ≥6 years.

Congenital & Chromosomal Conditions

Down syndrome (Q90.x): Trisomy 21 results in characteristic facial features, hypotonia, intellectual disability, and substantially elevated risk for congenital heart defects (40–50%, most commonly AVSD), leukemia, and hypothyroidism. Associated conditions should be coded separately. (CDC Down Syndrome)

Trisomy 13 (Q91.7) / Trisomy 18 (Q91.3): Autosomal trisomies with severe multisystem anomalies including CNS malformations, cardiac defects, and high neonatal mortality. Both are high-weight HHS-HCC categories due to extreme resource utilization.

Congenital heart disease (CHD): Structural defects of the heart or great vessels present at birth. “Major CHD” includes ventricular septal defect (Q21.0), tetralogy of Fallot (Q21.3), transposition of great vessels (Q20.3), hypoplastic left heart (Q23.4), and others. Surgical complexity and ongoing need for cardiology follow-up drive high risk-adjustment weights. (See related Congenital Heart Disease CDG)

Neuromuscular & Neurological Disorders

Spinal muscular atrophy (G12.0–G12.29): Autosomal recessive disorder caused by deletions/mutations in the SMN1 gene, causing anterior horn cell degeneration and progressive muscle weakness. SMA type 1 (Werdnig-Hoffmann, G12.0) presents in infancy with severe hypotonia; without treatment, most die before age 2. Disease-modifying therapies (nusinersen, onasemnogene abeparvovec, risdiplam) have dramatically altered the natural history. (NINDS SMA)

Muscular dystrophy (G71.0): Group of inherited myopathies; Duchenne MD (DMD) is the most common severe form, caused by dystrophin gene (Xp21) deletions, affecting ~1:3,500 male births. Progressive proximal weakness, loss of ambulation by early teens, cardiomyopathy, and respiratory failure are hallmarks. Dystrophin-targeting therapies (exon-skipping) and ataluren are in use. (CDC Muscular Dystrophy)

Cerebral palsy (G80.x): Non-progressive disorder of movement and posture resulting from damage to the developing brain. Types include spastic (most common, G80.0–G80.2), dyskinetic (G80.3), ataxic (G80.4). Associated conditions — epilepsy, intellectual disability, autism — frequently co-exist and each should be coded separately as they independently risk-adjust.

Epilepsy (G40.x): Recurrent unprovoked seizures. Code specificity requires seizure type (focal vs. generalized), intractability, and status epilepticus. Intractable epilepsy carries higher HHS-HCC weight. See the related Epilepsy CDG for full coding guidance.

Behavioral & Developmental Conditions

Autism spectrum disorder (F84.0–F84.9): Neurodevelopmental condition characterized by deficits in social communication/interaction and restricted, repetitive behaviors. DSM-5 consolidates all subtypes under ASD with three severity levels (requiring support, requiring substantial support, requiring very substantial support). Prevalence is ~1 in 36 children per CDC ADDM 2023 data. ASD maps to HHS-HCC in commercial/exchange models.

Intellectual disabilities (F70–F79): Significant limitations in intellectual functioning (IQ typically <70) and adaptive behavior, originating before age 18. Severity levels (mild, moderate, severe, profound) must be specified. The etiology should also be coded when known (e.g., Down syndrome, fragile X syndrome Q99.2).

Endocrine & Nutritional

Type 1 diabetes mellitus (E10.x): Autoimmune destruction of pancreatic beta cells, resulting in absolute insulin deficiency. Children present with DKA and require lifelong insulin therapy. Code complications when present (nephropathy, retinopathy, neuropathy, hypoglycemia) as they carry additional HHS-HCC weight. (ADA Standards of Care 2022)

Pediatric severe obesity (Z68.53–Z68.54): BMI ≥35 kg/m² (Z68.53) or ≥40 kg/m² (Z68.54) for ages 2–19, using CDC age- and sex-specific growth charts. Extreme pediatric obesity maps to the Morbid Obesity HHS-HCC category, reflecting elevated predicted costs related to cardiometabolic risk, sleep apnea, orthopedic complications, and psychosocial burden.

💊 Medication Impact / Treatment

Medications used to treat pediatric risk-adjusting conditions both confirm the diagnosis and — in some models — directly trigger risk category assignment in CDPS+Rx (which includes pharmacy data). Key medication classes and their coding implications:

Preview ends here. The full guide continues with FY2026 ICD-10-CM code sets, CPT surgical coding, MS-DRG mapping, reimbursement guidance, CDI query templates, and an audit checklist — all available to CCO Members.

← Back to All Clinical Documentation Guides

📘 ICD-10-CM Guidelines (FY2026)

The following guidelines from the FY2026 ICD-10-CM Official Guidelines for Coding and Reporting are critical for pediatric risk-adjusting conditions.

Section I.C. — Chapter-Specific Guidelines

• Sickle cell disease (Chapter 3 — D50–D89): Code the type of crisis when present (e.g., D57.00 Hb-SS with vaso-occlusive pain, unspecified; D57.01 with acute chest syndrome). “Sickle-cell trait” (D57.3) is NOT a disease — do not assign disease codes for trait carriers without clinical manifestation.
• Diabetes mellitus (Chapter 4 — E08–E13): Type 1 DM (E10.x) should be coded with the appropriate 4th and 5th characters to identify complications. When a patient uses an insulin pump, assign Z96.41 (presence of insulin pump) as an additional code.
• Cystic fibrosis (Chapter 4): E84.0 (CF with pulmonary manifestations) and E84.19 (CF with other GI manifestations) may be assigned together. Assign the manifestation codes additionally when documented (e.g., bronchiectasis J47.x, malabsorption K90.3).
• Congenital malformations (Chapter 17 — Q00–Q99): Q-code conditions are always reportable, even in adults, when they continue to affect patient management. Do not assume they are “historical” once the patient is discharged from NICU.
• Autism spectrum (Chapter 5 — F01–F99): Per DSM-5 alignment, code F84.0 (Autistic disorder) for ASD Level 1–3. When intellectual disability co-exists, assign a code from F70–F79 additionally. Language impairment (F80.x) and associated conditions should each be coded separately.
• Intellectual disability (Chapter 5): Assign the severity code (F70–F73, F78, F79). When caused by a known condition (e.g., Down syndrome), code the underlying condition first if it is the focus of the encounter.
• Malnutrition (Chapter 4): Malnutrition codes (E40–E46) should be assigned based on documented dietitian or physician assessment using validated tools. Coders should NOT assume or assign malnutrition from BMI/weight data alone without physician documentation.
• Perinatal conditions (Chapter 16 — P00–P96): P07.xx codes (disorders related to short gestation and low birth weight) are used only during the perinatal period OR when the condition directly affects current management in later encounters. After the perinatal period, use Z87.39 (personal history of conditions from perinatal period) unless the condition continues to affect care.
• Cancer (Chapter 2 — C00–D49): Active malignancy codes (C00–C96) are assigned when treatment is active. Once treatment is complete and no evidence of disease remains, assign Z85.x (history of cancer). Do NOT code “history of” with an active treatment code simultaneously.
• BMI in children (Chapter 21 — Z68.x): Z68.5x codes are for pediatric patients ages 2–20 only, using BMI-for-age percentile from CDC charts. Z68.53 = BMI ≥85th <95th (NOT risk-adjusting), Z68.53 = Class I obesity (≥95th pctl–<120%), Z68.54 = Class 2/3 extreme obesity (≥120% of 95th pctl or BMI ≥35). Use E66.01 (Morbid (severe) obesity due to excess calories) as the principal/first-listed code; Z68.5x as additional.

Additional Coding Guidance

• Cerebral palsy: Assign G80.x based on type and distribution. G80.0 (spastic quadriplegic), G80.1 (spastic diplegic), G80.2 (spastic hemiplegic), G80.3 (athetoid), G80.4 (ataxic). Associated epilepsy (G40.x) and intellectual disability (F70–F79) are coded additionally.
• ADHD with comorbidities (F90.x): ADHD alone does not consistently trigger HHS-HCC assignment. When documented with significant psychiatric comorbidities (e.g., bipolar disorder F31.x, schizophrenia F20.x, conduct disorder F91.x), the comorbid condition drives the RA value. Code all documented diagnoses.
• Developmental delay: F88 (Other disorders of psychological development) and F89 (Unspecified disorder of psychological development) are low-specificity codes. Query the provider to determine whether criteria for ASD (F84.0), intellectual disability (F70–F79), or specific developmental disorder (F80–F81) are met before assigning F88/F89.
• Well-child visits: Z00.121 (encounter for routine child health examination with abnormal findings) triggers obligation to code the abnormal finding. Z00.129 (without abnormal findings) should be used when the child is fully healthy. If a chronic condition is monitored at the well-child visit, it should still be coded as an additional diagnosis.

🔢 ICD-10-CM Code Set (FY2026)

The following table presents the primary FY2026 ICD-10-CM codes for pediatric risk-adjusting conditions. All codes verified against the FY2026 ICD-10-CM tabular list.

🔎 Indexing

The following ICD-10-CM Alphabetic Index pathways guide coders to the correct codes for major pediatric risk-adjusting conditions. All index references are per the FY2026 ICD-10-CM Official Index.

• Sickle cell: Disease, sickle-cell → Hb-SS → see D57.0x (with crisis subterms) or D57.1 (without crisis)
• Hemophilia A: Hemophilia → A (classical) → D66; with inhibitor → see D68.311
• Cystic fibrosis: Fibrosis, cystic → see E84; with pulmonary manifestations → E84.0; with meconium ileus → E84.11
• Down syndrome: Syndrome, Down → see Q90; trisomy, 21 → Q90.0 (meiotic nondisjunction)
• SMA: Atrophy, muscle, spinal → progressive; infantile (Werdnig-Hoffmann) → G12.0; Kugelberg-Welander → G12.21
• Muscular dystrophy: Dystrophy, muscular → Duchenne → G71.01; Becker → G71.02
• Cerebral palsy: Palsy, cerebral → spastic; quadriplegic → G80.0; diplegic → G80.1; hemiplegic → G80.2
• Autism: Disorder, autistic → F84.0; Asperger → F84.5
• Intellectual disability: Disability, intellectual → mild → F70; moderate → F71; severe → F72; profound → F73
• Asthma: Asthma → severe persistent → uncomplicated → J45.50; with exacerbation → J45.51; with status asthmaticus → J45.52
• Type 1 DM: Diabetes, type 1 → E10; with complication → see specific 4th/5th character subterms
• Obesity (pediatric): Obesity → morbid → E66.01; BMI → pediatric → ≥95th percentile → Z68.54
• Failure to thrive: Failure, thrive (child) → R62.51; Malnutrition → moderate protein-calorie → E44.0
• Preterm newborn: Newborn, premature → see also P07.3x; low birth weight → P07.0x–P07.1x
• Epilepsy: Epilepsy → generalized → idiopathic → not intractable → G40.309; intractable → G40.319

🏥 CPT (2026)

The following CPT codes are used for pediatric evaluation, management, developmental screening, and procedures related to risk-adjusting conditions. All codes verified per AMA CPT 2026.

🧾 HCPCS (2026)

HCPCS Level II codes used in pediatric risk-adjusting condition management. Codes verified against CMS HCPCS 2026 quarterly release.

📚 AHA Coding Clinic (Recent Guidance)

The following AHA Coding Clinic references provide official guidance on pediatric risk-adjusting conditions. Coders and CDI specialists should consult Coding Clinic as the authoritative source for ICD-10-CM coding questions.

• Sickle cell disease: Coding Clinic has confirmed that sickle cell crisis types (vaso-occlusive, acute chest syndrome, splenic sequestration, stroke) should be coded specifically when documented. “Sickle cell disease” alone (without crisis specification) defaults to D57.1; query providers to identify crisis type for more specific code assignment.
• Autism spectrum disorder: Coding Clinic guidance supports coding ASD (F84.0) with intellectual disability (F70–F73) and developmental language disorder (F80.x) as separately reportable conditions when each is documented and affects patient care.
• Cerebral palsy with epilepsy: Coding Clinic confirms that epilepsy occurring in a patient with cerebral palsy is coded separately (G40.x) and is not integral to the CP diagnosis. Both conditions are reportable and both risk-adjust independently.
• Malnutrition in children: Recent Coding Clinic guidance emphasizes that malnutrition (E40–E46) requires explicit physician or dietitian documentation — coders may NOT assign malnutrition based solely on low weight-for-age or laboratory values. CDI queries are appropriate when malnutrition is clinically suspected but not explicitly documented.
• Cystic fibrosis manifestations: Coding Clinic supports coding multiple CF manifestation codes (e.g., E84.0 + E84.19) when both pulmonary and intestinal manifestations are present and documented. CF-related diabetes mellitus is coded with E13.x (other specified diabetes) rather than E10 or E11.
• Preterm newborn in post-neonatal period: Coding Clinic guidance clarifies that P07.xx codes apply during the birth episode and the neonatal period (<28 days). After discharge from the NICU for a post-neonatal encounter, use Z87.39 (personal history) unless the prematurity-related condition directly affects current management.
• BMI pediatric codes: Coding Clinic confirms that Z68.5x codes are age-specific for patients 2–20 and must be assigned using CDC BMI-for-age growth charts. These are always secondary codes; E66.01 or other primary obesity code is sequenced first.

💰 HCC / Risk Adjustment (v28)

The following table maps key pediatric ICD-10-CM codes to their HHS-HCC categories under the ACA HHS-HCC concurrent risk adjustment model (used for commercial and exchange plans) and notes CMS-HCC v28 applicability. Note: CMS-HCC v28 (Medicare) has very limited pediatric application; HHS-HCC is the primary model for children.

✍️ CDI Query Templates

The following query templates are designed to be compliant with AHIMA/ACDIS CDI query guidelines — non-leading, multiple-choice, clinician-driven. Queries should be presented as formal documentation requests, not suggestions of a specific answer.

🧑‍⚕️ Treatments (Clinical)

The following summarizes current evidence-based treatment approaches for major pediatric risk-adjusting conditions. This section provides clinical context to help CDI specialists understand what constitutes active, ongoing management requiring continued diagnosis coding.

Sickle Cell Disease

Management includes hydroxyurea (first-line disease-modifying agent for HbSS/HbSβ⁰), FDA-approved newer agents (crizanlizumab for vaso-occlusion prevention, voxelotor for hemolysis), chronic transfusion therapy for stroke prevention, and hematopoietic stem cell transplant (HSCT) as the only current curative option. Gene therapy approaches (betibeglogene autotemcel/Zynteglo, exagamglogene autotemcel/Casgevy) received FDA approval in 2023 for eligible patients ≥12 years.

Cystic Fibrosis

CFTR modulator therapy has transformed CF management for patients with eligible mutations. Elexacaftor/tezacaftor/ivacaftor (Trikafta/Kaftrio) is approved for patients ≥2 years with at least one F508del allele, achieving sustained FEV1 improvement and dramatic reduction in exacerbations. Airway clearance therapy (ACT), inhaled antibiotics, pancreatic enzyme replacement therapy (PERT), and CF dietitian management remain foundational components. Lung transplant for advanced disease.

Spinal Muscular Atrophy

Disease-modifying therapies include: intrathecal nusinersen (Spinraza, approved all ages and types), IV onasemnogene abeparvovec-xioi (Zolgensma, approved <2 years or <21 kg), and oral risdiplam (Evrysdi, approved ≥2 months). Multidisciplinary care includes respiratory support (non-invasive ventilation, cough assist), nutritional management (gastrostomy tube), and orthopedic management (scoliosis, contractures). Early treatment of pre-symptomatic SMA (newborn screening) has become standard of care in states with NBS programs. (NINDS SMA)

Cerebral Palsy

Multidisciplinary management focuses on maximizing function: physical therapy (PT), occupational therapy (OT), speech-language pathology (SLP), orthotics/AFOs, intrathecal baclofen pump (ITB) for spasticity, selective dorsal rhizotomy (SDR), botulinum toxin injections (BTX-A), and orthopedic surgery (hip reconstruction, hamstring lengthening). Associated epilepsy managed with AEDs; associated ID with educational and behavioral supports.

Autism Spectrum Disorder

Evidence-based interventions include applied behavior analysis (ABA) — the most extensively studied behavioral intervention for ASD — early intensive behavioral intervention (EIBI), speech-language therapy, occupational therapy, social skills training, and family support/caregiver training. Pharmacotherapy (aripiprazole, risperidone) for irritability/self-injurious behavior associated with ASD. No FDA-approved treatment for core ASD symptoms. (AAP Autism Guidance)

Type 1 Diabetes Mellitus

Insulin therapy is mandatory (multiple daily injections or continuous subcutaneous insulin infusion/CSII). Continuous glucose monitoring (CGM) is standard of care. HbA1c target <7% per ADA Standards of Care 2023 (individualized). Closed-loop systems (artificial pancreas) improve glycemic control. Annual screening for complications (microalbuminuria, retinopathy, thyroid) from diagnosis + 5 years or onset of puberty.

Severe Persistent Asthma

NHLBI EPR-3/GINA step 5–6 therapy: high-dose ICS + LABA as foundation; add-on biologics for eligible patients ≥6 years (anti-IgE: omalizumab; anti-IL-5: mepolizumab/reslizumab; anti-IL-5Rα: benralizumab; anti-IL-4Rα: dupilumab; anti-TSLP: tezepelumab ≥12 years). Allergen immunotherapy as adjunct. Bronchial thermoplasty not approved for children. Pulmonology/allergy co-management recommended. Asthma action plan, spacer use, avoidance counseling.

🎓 Patient Education / Summary

For CDI and coding teams working with pediatric practices and health plans, the following key takeaways summarize the risk adjustment coding priorities for children with complex chronic conditions:

For Coding and CDI Teams

• Model awareness: Children on ACA exchange plans are subject to HHS-HCC concurrent risk adjustment. Children on Medicaid MCO plans are primarily subject to state CDPS+Rx models. Understanding which model applies determines which code categories drive payment.
• Capture at every encounter: Unlike adult Medicare, HHS-HCC is concurrent — diagnoses from any encounter type (preventive, acute, specialist) during the benefit year count. Document and capture all chronic conditions at every qualifying visit.
• Specificity matters: Non-specific codes (F89, J45.9, G80.9) carry lower or no HCC weight. Query providers to elevate to specific codes (F84.0, J45.50, G80.0) that trigger appropriate HCC assignment.
• Co-morbidities stack: A child with cerebral palsy, epilepsy, and intellectual disability has three independently risk-adjusting diagnoses. Each must be supported by documentation and coded at every encounter where each condition affects management.
• Well-child visit opportunity: The annual well-child exam is the highest-yield encounter for risk adjustment capture because ALL active conditions are typically reviewed. Ensure the claim reflects every chronic condition reviewed during the visit.
• Documentation required: Medication lists and problem lists alone do NOT support risk adjustment claims — only face-to-face encounter notes with supporting clinical documentation. CDI teams should focus on ensuring narrative encounter notes explicitly support each diagnosis code.

Patient / Family Education Points

When preparing patient and family education materials related to complex pediatric conditions that risk-adjust:

• Explain the importance of attending ALL scheduled appointments — primary care, specialist, behavioral health — as each encounter captures the conditions that help ensure adequate resources and coverage for your child’s care.
• Maintain an up-to-date, written diagnosis list including all chronic conditions, medications, and specialists. Bring this to every appointment so the team can document all active conditions.
• Understand that “administrative” diagnoses (the codes on your child’s insurance claims) must reflect what is happening clinically. If your child’s diagnoses have become more or less specific, work with your care team to update documentation.
• For children transitioning from pediatric to adult care (typically age 18–21), ensure that diagnoses are transferred accurately to the new adult provider’s documentation system and that ACA/Medicaid enrollment transitions are managed to preserve continuity of risk-adjustment coding.
• Families of children with CSHCN can contact their health plan’s care management team or state CSHCN program for coordination support. Organizations such as Family Voices and the Association of Maternal and Child Health Programs (AMCHP) provide resources for navigating complex pediatric healthcare.

About this Guide

This Clinical Documentation Guide is published by CCO Academy and is intended for credentialed coding, CDI, and clinical documentation professionals. Content is updated for FY2026 ICD-10-CM (effective October 1, 2025). All code assignments should be verified against the official ICD-10-CM Tabular List, AHA Coding Clinic, and applicable payer-specific policies. This guide does not constitute legal, medical, or compliance advice.

Last reviewed: April 2026 · Next scheduled review: October 2026 (FY2027 update)